Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on August 30, 2012. The report details a strategic transaction with Professional Compounding Centers of America, Inc. ("PCCA") and the establishment of a new scientific and regulatory advisory board.
Key Financial Metrics
The filing reports the following specific financial activity:
- Capital Raised: $4,000,000 in aggregate gross proceeds.
- Shares Issued: 4,163,414 shares of common stock.
- Price Per Share: $0.96075.
- Transaction Date: Agreements entered August 30, 2012; closed August 31, 2012.
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the execution of two agreements with PCCA:
- License Agreement: PCCA granted Imprimis exclusive rights to proprietary formulations, technologies, and data. Imprimis agreed to pay royalties on net sales of future products. The agreement includes termination clauses if Imprimis fails to commence R&D efforts within specified timeframes.
- Stock Purchase Agreement: Imprimis sold unregistered shares to PCCA under Section 4(2) of the Securities Act of 1933. PCCA is an accredited investor purchasing for its own account.
Outlook, Management Commentary, and Risks
Advisory Board Establishment: The Board of Directors approved a scientific and regulatory advisory board to guide clinical trial procedures and product development. The board consists of three members:
- Dr. Gerald J. Yakatan: Expertise in drug development and FDA approval processes.
- Dr. Lee S. Simon: Former FDA division director and NIH investigator.
- Dr. Allan Green: Physician, attorney, and inventor with biomedical management experience.
Consulting Agreements: The Company entered into independent contractor agreements with SDG, LLC (principals Dr. Simon and Dr. Green) and Dr. Yakatan to provide services on clinical development strategy and regulatory affairs.
Risks and Contingencies: The License Agreement is contingent upon Imprimis commencing research and development efforts within certain time periods to avoid termination. The shares issued are restricted securities and cannot be resold without registration or an exemption.
Investor Verification Checklist
- Verify the full text of the PCCA License Agreement (Exhibit 10.1) to understand specific royalty rates and R&D milestones.
- Confirm the dilution impact of the 4,163,414 new shares on existing shareholders.
- Review the consulting agreements to determine the financial obligations to the new advisory board members.
- Monitor future filings for evidence of R&D commencement to ensure the License Agreement remains in force.